当前位置: 首页 > 期刊 > 《糖尿病新世界》 > 2017年第2期
编号:13067653
丝氨酸蛋白酶抑制物在2型糖尿病合并颈动脉粥样硬化患者中的意义(2)
http://www.100md.com 2017年1月15日 《糖尿病新世界》 2017年第2期
     [參考文献]

    [1] Nathan DM. Some answers,more controversy,from UKPDS. United Kingdom prospective diabetes study[J].Lancet,1998(352):832-833.

    [2] Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor:a unique insulin-sensitizing adipocytokine in obesity[J].Proceedings of the National Academy of Sciences of the United States of America, 2005, 102(30):10610-10615.

    [3] Gulcelik NE, Karakaya J, Gedik A, et al. Serum vaspin levels in type 2 diabetic women in relat- ion to microvascular complications[J].European journal of endocrinology, 2009, 160(1):65-70.

    [4] Tan BK, Heutling D, Chen J, et al. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance[J]. Diabetes, 2008,57(6):1501-1507.

    [5] Li Z, Ma C, Li L, et al. Vaspin serum concentration in patients with type 2 diabetes and carotid plaque[J].The Journal of International Medical Research,2012(40):1670-1676.

    (收稿日期:2016-10-11), http://www.100md.com(马竞轩 许娜 张云良 马朝朋 郭淑芹)
上一页1 2